Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Martin Gelbard

Urology Santa Monica, CA Medical Doctor

NPI 1912996851 CMS profile 269175

1260 15Th St Ste 1200, Santa Monica, CA 90404

Open in the dashboard

General payments

$142,287

196 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Martin Gelbard of Santa Monica, CA is reported in the CMS Open Payments database as having received $142,287 across 196 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $542 2
2024 General $14,814 27
2023 General $11,743 25
2022 General $12,399 35
2021 General $34,760 27
2020 General $16,760 20
2019 General $51,268 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Martin Gelbard
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Martin Gelbard were reported at $542. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Martin Gelbard Urology median Middle half National median
2019 $51,268 $480 $147–$1,201 $163
2020 $16,760 $246 $87–$645 $114
2021 $34,760 $358 $111–$1,000 $132
2022 $12,399 $476 $143–$1,263 $149
2023 $11,743 $560 $168–$1,461 $160
2024 $14,814 $563 $170–$1,464 $164
2025 $542 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Endo Pharmaceuticals Inc. $125,263 128 payments
  2. Endo USA, Inc. $14,966 28 payments
  3. Metuchen Pharmaceuticals $1,557 2 payments
  4. Rochester Medical Corporation $282 23 payments
  5. C. R. Bard, Inc. & Subsidiaries $171 11 payments
  6. Progenics Pharmaceuticals, Inc. $13 1 payment
  7. Medtronic USA, Inc. $12 1 payment
  8. Astellas Pharma US Inc $11 1 payment
  9. Clarus Therapeutics Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $70,985 25 payments
  2. Consulting Fee $50,848 12 payments
  3. Travel and Lodging $15,305 58 payments
  4. Food and Beverage $5,149 101 payments
Products named General payments · program years 2019–2025
  1. XIAFLEX $140,229 156 payments
  2. Stendra $1,557 2 payments
  3. Bard Urinary Drainage Bag $171 11 payments
  4. AVEED $167 1 payment
  5. EDEX $167 1 payment
  6. PYLARIFY $13 1 payment
  7. INTERSTIM $12 1 payment
  8. XTANDI $11 1 payment
  9. MYRBETRIQ $11 1 payment
  10. JATENZO $11 1 payment
  11. Other $23 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

196 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record